Twist Bioscience Corp
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
| Nine months ended June 30, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Operating activities | ||
| Net loss | $(109,579) | $(50,532) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 19,386 | 18,849 |
| Stock-based compensation expense | 50,385 | 48,376 |
| Gain on sale of business | — | (48,847) |
| Other non-cash adjustments[1] | (673) | 1,963 |
| Changes in assets and liabilities: | ||
| Accounts receivable, net[1] | (8,497) | (15,172) |
| Inventories | (6,852) | (1,861) |
| Prepaid expenses and other current assets[1] | (18,960) | (1,822) |
| Other non-current assets | (302) | (603) |
| Accounts payable | 4,580 | 9,616 |
| Accrued compensation | 3,601 | (4,692) |
| Accrued expenses and other liabilities | 25,653 | 8,911 |
| Net cash used in operating activities | $(41,258) | $(35,814) |
| Investing activities | ||
| Purchases of property and equipment | $(27,624) | $(15,577) |
| Purchase of intangible asset | (100) | — |
| Purchases of investments | (38,462) | (28,257) |
| Proceeds from maturity of investments | 38,350 | 28,975 |
| Proceeds from sale of business | — | 2,500 |
| Cash paid for asset acquisition | (5,000) | — |
| Cash paid for investment in equity securities | (1) | — |
| Net cash used in investing activities | $(32,837) | $(12,359) |
| Financing activities | ||
| Proceeds from exercise of stock options | $5,882 | $5,551 |
| Proceeds from the issuance of liability related to sale of future revenue | — | 15,000 |
| Proceeds from issuance under employee stock purchase plan | 2,357 | 2,429 |
| Repurchases of common stock for income tax withholding | (16) | (14) |
| Net cash provided by financing activities | $8,223 | $22,966 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | $13 | $(20) |
| Net decrease in cash, cash equivalents, and restricted cash | (65,859) | (25,227) |
| Cash, cash equivalents, and restricted cash at beginning of period | 185,425 | 229,132 |
| Cash, cash equivalents, and restricted cash at end of period | $119,566 | $203,905 |
|---|---|---|
| Supplemental disclosure of cash flow information | ||
| Income taxes paid, net of refunds | $529 | $23 |
| Non-cash investing and financing activities | ||
| Property and equipment additions included in accounts payable and accrued expenses | $3,343 | $1,822 |
| Equity securities received as consideration for sale of business | $— | $53,890 |
| Promissory note receivable received as consideration for sale of business | $— | $1,696 |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $24,773 | $— |
| Issuance of common stock for investment in equity securities | $13,750 | $— |
| Issuance of common stock in connection with asset acquisition | $10,000 | $— |
| Liability for issuance of common stock in connection with asset acquisition | $5,000 | $— |
[1]Includes immaterial changes in a related party's balances.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.